REGULATORY

• Chuikyo Payer Rep Floats Deferred Price Cuts for PMP upon Generic Entries
  August 31, 2023

• MHLW Top Pharma Officer Remains Committed to Fast, Safe Access to Good Drugs
  August 31, 2023

• MHLW to Unveil Draft of 2nd Package Strategy for SaMD on Sept. 6
  August 31, 2023

• MHLW to Issue Development Requests for New Uses of Rituxan, Truvada, and More
  August 31, 2023

• Medical DX Office to Kick Off in September, Explore Better Use of Medical Data for Drug Discovery
  August 30, 2023

• MHLW Orders Label Revisions for Prazaxa, Smyraf, and More
  August 30, 2023

• MHLW Panel OKs Inclusion of 5-in-1 Vaccine in National Immunization Program
  August 30, 2023

• Label Revisions Ordered for CAR-T Therapies on Out-of-Spec Products
  August 30, 2023

• Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
  August 29, 2023

• Kazunari Asanuma to Lead MHLW Health Policy Bureau
  August 29, 2023

• MHLW to Seek Funds for Survey to Streamline Generic Manufacturing: FY2024 Request
  August 28, 2023

• MHLW to Book Budget to Launch Regulatory Advisory Center for Pediatric, Orphan Meds for FY2024
  August 28, 2023

• MHLW to Seek 33.7 Trillion Yen Budget for FY2024
  August 28, 2023

• Japan to Shell Out Up to 30 Billion Yen for National Project to Spur Dementia R&D
  August 28, 2023

• Shunichi Kuryu to Take Helm at New Infectious Disease Agency
  August 28, 2023

• MHLW Eyes Pediatric, Orphan Drug Advisory Team within PMDA: FY2024 Budget Request
  August 25, 2023

• Japan Grants Orphan Tag to Efzofitimod, 3 More APIs
  August 25, 2023

• Drug Pricing Organization Proposes Changes in PMP, Re-Pricing Criteria towards 2024 Reform
  August 24, 2023

• Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
  August 24, 2023

• Lyfnua to Get 7.7% Price Cut in November, Retevmo Analysis Results Reported: CEA
  August 24, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 75
• 76
• 77
• 78
• 79
• 80
• 81
• 82
• 83
• …
• Next ›
• 最終 »